Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity
- 24 September 2010
- journal article
- research article
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 200 (2) , 77-83
Abstract
Early detection of hepatitis C virus (HCV) is an important step in preventing progression to cirrhosis and hepatocellular carcinoma. Serologic assays for anti-hepatitis C (anti-HCV) antibody are valuable first-line tests in the screening and diagnosis of HCV infection. The aim of this multicenter study was to compare the Elecsys® Anti-HCV assay with alternative CE-marked Anti-HCV antibody assays against a range of samples that included 1,138 blood donors, 3,553 unselected routine daily specimens, and 46 pre-selected seroconversion panels. Specificity of the Elecsys Anti-HCV assay was 99.5% with blood donor samples and 99.4% with routine clinical specimens. These were similar to those obtained with the Prism® Anti-HCV, Architect® Anti-HCV assay, ADVIA® Centaur Anti-HCV assay and Vitros® Eci aHCV assays. Seroconversion sensitivity for the Elecsys Anti-HCV assay was similar to that of the Architect Anti-HCV, AxSYM HCV version 3.0, ADVIA Centaur Anti-HCV, and Vitros Eci aHCV assays. In fact, seroconversion testing on 46 commercially available panels showed that the difference in first detecting a positive blood sample was less than one day between assays (not statistically significant). The Elecsys Anti-HCV assay as well as the Architect, Prism, and Vitros Anti-HCV immunoassays revealed a seroconversion sensitivity of 100%, whereas the ADVIA Centaur HCV immunoassay showed a sensitivity of only 97.5% (39/40). Overall, the performance of the Elecsys Anti-HCV assay was similar to the performances of the comparator CE-marked Anti-HCV antibody assays.Keywords
This publication has 14 references indexed in Scilit:
- Infectious diseasesClinical Chemistry and Laboratory Medicine (CCLM), 2009
- Clinical Performance Evaluation of Four Automated Chemiluminescence Immunoassays for Hepatitis C Virus Antibody DetectionJournal of Clinical Microbiology, 2008
- Sensitivities of CE-marked HIV, HCV, and HBsAg assaysJournal of Medical Virology, 2007
- Performance characteristics of the ARCHITECT® Anti-HCV assayJournal of Clinical Virology, 2005
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Global Burden of Disease (GBD) for Hepatitis CThe Journal of Clinical Pharmacology, 2004
- Laboratory Assays for Diagnosis and Management of Hepatitis C Virus InfectionJournal of Clinical Microbiology, 2003
- Use and interpretation of virological tests for hepatitis CHepatology, 2002
- Use and interpretation of virological tests for hepatitis CHepatology, 2002
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989